Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed) | RFA AR 19 006

Opportunity Information: Apply for RFA AR 19 006

The National Institutes of Health (NIH), through the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), offered this grant opportunity to support mechanistic ancillary studies that can be added onto clinical projects that are already up and running. The core idea is to fund focused, time-sensitive research that digs into biological or disease mechanisms while taking advantage of the people, samples, data, and operational setup already created by an existing clinical study. The award uses the R01 mechanism and is explicitly labeled “Clinical Trial Not Allowed,” meaning the funded work is intended to be mechanistic and ancillary rather than launching a new clinical trial under this application.

This opportunity is designed for situations where a parent clinical project is actively enrolling participants or actively collecting clinical data and/or biospecimens, and an additional mechanistic question can be answered efficiently by piggybacking on that existing effort. The parent project can be an interventional clinical trial or a non-interventional clinical study such as an observational cohort, as long as it provides a well-characterized participant group and the necessary infrastructure (for example, consent procedures, clinical assessments, data management systems, sample collection and storage, and established workflows). The ancillary study is expected to leverage those existing resources rather than recreate them, which is one reason the program emphasizes speed and “time-sensitive” work.

The scientific goal is to increase the value of ongoing investments by extracting deeper mechanistic insight from clinical studies that are already funded privately or publicly. In practice, that means an applicant would propose experiments or analyses that help explain how a disease works, how an organ system is affected, or why certain clinical outcomes occur, within areas aligned to the NIAMS mission (arthritis and rheumatic diseases, musculoskeletal biology and diseases, and skin biology and diseases). By adding mechanistic endpoints or deeper laboratory, molecular, cellular, genetic, immunologic, or biomarker-oriented analyses to an existing clinical framework, the ancillary project is meant to strengthen the parent study and produce findings that can point toward better diagnostics, new treatment targets, improved prevention strategies, or more precise ways to classify disease.

A notable operational feature of the FOA is that applications were intended to go through an accelerated review and award process. The rationale is that ancillary studies often depend on narrow windows of opportunity: a cohort may only be available for a limited time, a trial may be nearing completion, a specific treatment exposure period may be ending, or key samples may only be collectable at certain visits. Speed matters because missing those windows can make the ancillary science impossible or much less informative.

In terms of who could apply, the eligible applicant pool was broad and included many types of U.S.-based organizations and governments. Eligible applicants included state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations other than federally recognized governments; public housing authorities/Indian housing authorities; nonprofit organizations (both 501(c)(3) and non-501(c)(3), excluding higher education institutions where applicable); for-profit organizations other than small businesses; and small businesses. The FOA also explicitly highlighted additional eligible applicant categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions.

There were also important limits around foreign involvement. Non-domestic (non-U.S.) entities (foreign organizations/institutions) were not eligible to apply as the applicant organization, and non-domestic components of U.S. organizations were not eligible to apply. At the same time, “foreign components” as defined by the NIH Grants Policy Statement were allowed, meaning a U.S. applicant could, under NIH rules, include certain foreign activities or collaborations if they meet NIH’s definition and requirements for a foreign component.

Administratively, this was a discretionary grant program under the NIH, categorized under health research (CFDA 93.846). The funding opportunity number was RFA-AR-19-006, and it had an original closing date of April 2, 2019. The listed award ceiling was $300,000, indicating an upper bound on the amount NIH expected to provide per award under this announcement. The overarching intent was not to fund a brand-new standalone clinical project, but to strategically add mechanistic depth to an existing clinical effort in a way that increases the overall scientific return and advances understanding of NIAMS-relevant diseases and organ systems.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.846.
• This funding opportunity was created on 2018-04-04.
• Applicants must submit their applications by 2019-04-02. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $300,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA AR 19 006

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: